LENZ Therapeutics (LENZ) Cash & Equivalents (2020 - 2026)

LENZ Therapeutics (LENZ) has 7 years of Cash & Equivalents data on file, last reported at $24.8 million in Q1 2026.

• Quarterly Cash & Equivalents rose 7.51% year-over-year to $24.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $24.8 million (up 7.51% YoY) and the FY2025 annual result came in at $25.2 million, up 24.91% from the prior year.
• Cash & Equivalents slipped to $24.8 million in Q1 2026 per LENZ's latest filing, from $25.2 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $200.4 million in Q1 2024 and bottomed at $8.0 million in Q1 2023.
• The 5-year median for Cash & Equivalents is $41.0 million (2024), against an average of $70.6 million.
• The widest annual swing landed in 2023, when Cash & Equivalents tumbled 95.7%; it then jumped 2416.42% in 2024.
• Tracing LENZ's Cash & Equivalents over 5 years: stood at $47.7 million in 2022, then fell by 26.38% to $35.1 million in 2023, then slumped by 42.64% to $20.2 million in 2024, then advanced by 24.91% to $25.2 million in 2025, then declined by 1.62% to $24.8 million in 2026.
• Per Business Quant, the three latest LENZ Cash & Equivalents figures stand at $24.8 million (Q1 2026), $25.2 million (Q4 2025), and $25.4 million (Q3 2025).

Peer Comparison